Article

501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab <i>in vitro</i>

2021-02-16

Abstract excerpt

We generated several versions of the receptor binding domain (RBD) of the Spike protein with mutations existing within newly emerging variants from South Africa and Brazil. We found that the mutant RBD with K417N, E484K, and N501Y exchanges has higher binding affinity to the human receptor compared to the wildtype RBD. This mutated version of RBD also completely abolishes the binding to a therapeutic antibody, Bam...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5d156f63-4c84-593d-a2b5-2f68a0e936b2
DOI: 10.1101/2021.02.16.431305

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab <i>in vitro</i>DOI 10.1101/2021.02.16.431305Read

501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro.Semantic proximity Read

Effect of RBD mutations in spike glycoprotein of SARS-CoV-2 on neutralizing IgG affinitySemantic proximity Read

Effect of RBD mutations in spike glycoprotein of SARS-CoV-2 on neutralizing IgG affinitySemantic proximity Read

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against novel viral variantsSemantic proximity Read

Insights on SARS-CoV-2’s Mutations for Evading Human Antibodies: Sacrifice and SurvivalSemantic proximity Read

SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccinationSemantic proximity Read

In Silico Analyses on the Comparative Potential of Therapeutic Human Monoclonal Antibodies Against Newly Emerged SARS-CoV-2 Variants Bearing Mutant Spike ProteinSemantic proximity Read

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited seraSemantic proximity Read

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccinationSemantic proximity Read

<i>in silico</i> Assessment of Antibody Drug Resistance to Bamlanivimab of SARS-CoV-2 Variant B.1.617Semantic proximity Read

Structure-Function Analysis of Resistance to Bamlanivimab by SARS-CoV-2 Variants Kappa, Delta, and Lambda.Semantic proximity Read

The Lambda variant of SARS-CoV-2 has a better chance than the Delta variant to escape vaccinesSemantic proximity Read